Buscar
Innate Pharma SA
IPHAAñadir a la lista de seguimiento
1.800USD
-0.010-0.55%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
171.76MCap. mercado
PérdidaP/E TTM
Más Datos de Innate Pharma SA Compañía
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
Información de Innate Pharma SA
Símbolo de cotizaciónIPHA
Nombre de la empresaInnate Pharma SA
Fecha de salida a bolsaOct 31, 2006
Director ejecutivoDickinson (Jonathan Elliot)
Número de empleados181
Tipo de seguridadDepository Receipt
Fin del año fiscalOct 31
Dirección117 avenue de Luminy
CiudadMARSEILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísFrance
Código postal13009
Teléfono33430303030
Sitio Webhttps://www.innate-pharma.com/
Símbolo de cotizaciónIPHA
Fecha de salida a bolsaOct 31, 2006
Director ejecutivoDickinson (Jonathan Elliot)
Ejecutivos de Innate Pharma SA
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Dr. Irina Staatz-Granzer, Ph.D.
Dr. Irina Staatz-Granzer, Ph.D.
Chairwoman of the Board of Directors
Chairwoman of the Board of Directors
--
--
Mr. Yannis Morel, Ph.D.
Mr. Yannis Morel, Ph.D.
Chief Operating Officer, Executive Vice President, Member of the Executive Board, Member of the Leadership Team
Chief Operating Officer, Executive Vice President, Member of the Executive Board, Member of the Leadership Team
--
--
Ms. Veronique Chabernaud, M.D.
Ms. Veronique Chabernaud, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Prof. Jean-Yves Blay, Ph.D.
Prof. Jean-Yves Blay, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Ms. Odile Belzunce
Ms. Odile Belzunce
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
--
--
Ms. Odile Laurent
Ms. Odile Laurent
Vice President - Human Resources, Member of the Leadership Team
Vice President - Human Resources, Member of the Leadership Team
--
--
Ms. Pascale Boissel
Ms. Pascale Boissel
Independent Vice Chairwoman of the Supervisory Board
Independent Vice Chairwoman of the Supervisory Board
--
--
Mr. Olivier Martinez
Mr. Olivier Martinez
Member of the Supervisory Board, Representative of Bpifrance Participations
Member of the Supervisory Board, Representative of Bpifrance Participations
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Dr. Irina Staatz-Granzer, Ph.D.
Dr. Irina Staatz-Granzer, Ph.D.
Chairwoman of the Board of Directors
Chairwoman of the Board of Directors
--
--
Mr. Yannis Morel, Ph.D.
Mr. Yannis Morel, Ph.D.
Chief Operating Officer, Executive Vice President, Member of the Executive Board, Member of the Leadership Team
Chief Operating Officer, Executive Vice President, Member of the Executive Board, Member of the Leadership Team
--
--
Ms. Veronique Chabernaud, M.D.
Ms. Veronique Chabernaud, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Prof. Jean-Yves Blay, Ph.D.
Prof. Jean-Yves Blay, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Innate Pharma SA?
Los cinco principales accionistas de Innate Pharma SA son: Mr. Gilles Brisson
¿Cuántas instituciones poseen acciones de Innate Pharma SA (IPHA)?
A fecha de 2026Q1, 22 instituciones poseen acciones de Innate Pharma SA, con un valor de mercado combinado de aproximadamente 336.10K, lo que representa el 0.37% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 136136.00.